Alerts will be sent to your verified email
Verify EmailTATVA
Tatva Chintan Pharma
|
UPL
|
Grauer & Weil (I)
|
|
---|---|---|---|
Operational Metrics
|
|||
API Sector
|
|||
Total reactor capacity
|
294.0 kL | n/a | n/a |
Chemical Sector
|
|||
Capacity Utilization - Chemicals - Reactor
|
77.61 % | n/a | n/a |
Financials
|
|||
5 yr Average ROE
|
23.7 % | 12.62 % | 15.3 % |
5yr average Equity Multiplier
|
1.85 | 3.6 | 1.43 |
5yr Average Asset Turnover Ratio
|
0.86 | 0.52 | 0.95 |
5yr Avg Net Profit Margin
|
14.91 % | 6.74 % | 11.2 % |
Price to Book
|
3.6 | 1.73 | 4.89 |
P/E
|
87.29 | 0.0 | 26.93 |
5yr Avg Cash Conversion Cycle
|
141.97 Days | -56.93 Days | 24.62 Days |
Inventory Days
|
90.7 Days | 78.29 Days | 50.57 Days |
Days Receivable
|
60.72 Days | 95.0 Days | 52.87 Days |
Days Payable
|
78.36 Days | 229.19 Days | 82.08 Days |
5yr Average Interest Coverage Ratio
|
12.37 | 2.88 | 43.7 |
5yr Avg ROCE
|
25.2 % | 11.64 % | 19.27 % |
5yr Avg Operating Profit Margin
|
21.01 % | 20.36 % | 18.13 % |
5 yr average Debt to Equity
|
0.57 | 1.38 | 0.04 |
5yr CAGR Net Profit
|
17.24 % | 19.08 % | 12.08 % |
5yr Average Return on Assets
|
12.62 % | 3.57 % | 10.68 % |
Shareholdings
|
|||
Promoter Holding
|
72.02 % | 32.35 % | 69.05 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-7.15 % | 4.39 % | 0.0 |
Change in Mutual Fund Holding (3 Yrs)
|
9.42 % | 2.12 % | 0.0 |
Tatva Chintan Pharma
|
UPL
|
Grauer & Weil (I)
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Segment Break-Up
|
Segment Break-Up
|
Segment Break-Up
|
Segment Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|